1-20 of 138
Vivek Roy
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

First Results from the Dose Escalation Part of the Phase 1 Study of KTX1001, an Oral, First-in-Class, Potent Inhibitor of MMSET/NSD2 for Relapsed/Refractory Multiple Myeloma (RRMM)

Pierre Bories, Cristina Gasparetto, David Dingli, Sagar Lonial, Saad Z. Usmani, Jesus G Berdeja, Alfred Chung, Aimaz Afrough, Laura Rosiñol, Andrew J. Yee, Suzanne Trudel, David S. Siegel, Paula Rodríguez-Otero, Soo Bang, Terry Connolly, Chad A. Lewis, Erin Flynt, Julie Vazquez, Sanjana U. Miskin, Benjamin Winograd, Maria-Victoria Mateos, Cyrille Touzeau, Vivek Roy
Journal: Blood
Blood (2024) 144 (Supplement 1): 3370.
https://doi.org/10.1182/blood-2024-199174
Published: 2024
Journal Articles

Real World Outcomes with Venetoclax (Ven)-Based Therapies in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): A Mayo Clinic Comprehensive Cancer Center (MCCC) Experience

Ricardo D. Parrondo, Saurav Das, Hanna Sledge, Abiola Bolarinwa, Jamie Elliott, Andre Fernandez, David O. Hodge, Leif Bergsagel, Rafael Fonseca, Prashant Kapoor, Francis Buadi, Morie A. Gertz, Angela Dispenzieri, Vivek Roy, Taimur Sher, Moritz Binder, Nadine Abdallah, Saurabh Chhabra, S. Vincent Rajkumar, Wilson I. Gonsalves, Joselle Cook, David Dingli, Saurabh Zanwar, Yi Lin, Eli Muchtar, Caitlin Wilson, Udit Yadav, Rahma M Warsame, J E Wiedmeier-Nutor, Taxiarchis Kourelis, Nelson Leung, Madhu Nagaraj, Mustaqeem A. Siddiqui, Linda B. Baughn, Shaji Kumar, Asher A. Chanan-Khan, Sikander Ailawadhi
Journal: Blood
Blood (2024) 144 (Supplement 1): 1981.
https://doi.org/10.1182/blood-2024-208294
Published: 2024
Journal Articles

Outcomes of Venetoclax-Based Treatment Combinations in Relapsed/Refractory Multiple Myeloma: Real-World Practice Patterns and Impact of Cytogenetics on Outcomes

Abiola Bolarinwa, Madhu Nagaraj, Saurabh Zanwar, Nadine Abdallah, P. Leif Bergsagel, Moritz Binder, Francis Buadi, Saurabh Chhabra, Joselle Cook, David Dingli, Angela Dispenzieri, Morie A. Gertz, Wilson I. Gonsalves, Suzanne R Hayman, Prashant Kapoor, Taxiarchis Kourelis, Nelson Leung, Yi Lin, Eli Muchtar, Ricardo D. Parrondo, Vivek Roy, Taimur Sher, Mustaqeem A. Siddiqui, Rahma M Warsame, Amie Fonder, Miriam Hobbs, Yi Lisa Hwa, Michelle G. Rogers, Udit Yadav, J E Wiedmeier-Nutor, Dragan Jevremovic, Linda B. Baughn, Vincent Rajkumar, Rafael Fonseca, Sikander Ailawadhi, Shaji Kumar
Journal: Blood
Blood (2024) 144 (Supplement 1): 4728.
https://doi.org/10.1182/blood-2024-208736
Published: 2024
Journal Articles

Disparities in Multiple Myeloma (MM): Race/Ethnicity-Specific Sociodemographic and Economic Factors That May Drive Patient Decisions to Refuse Treatment

Firas Baidoun, Vivek Roy, Ricardo D. Parrondo, Andre Fernandez, Caitlin Flott, Taimur Sher, Rami Manochakian, Asher A. Chanan-Khan, Sikander Ailawadhi
Journal: Blood
Blood (2024) 144 (Supplement 1): 3790.
https://doi.org/10.1182/blood-2024-206308
Published: 2024
Journal Articles

Early Mortality in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Sociodemographic and Economic Factors Contributing to the Disparity

Firas Baidoun, Ricardo D. Parrondo, Vivek Roy, Andre Fernandez, Caitlin Flott, Taimur Sher, Rami Manochakian, Asher A. Chanan-Khan, Sikander Ailawadhi
Journal: Blood
Blood (2024) 144 (Supplement 1): 4723.
https://doi.org/10.1182/blood-2024-206351
Published: 2024
Journal Articles

Impact of Total Body Irradiation-Based Conditioning Regimens on Outcomes in Patients with Aggressive Mature T-Cell Lymphomas Undergoing Allogeneic Hematopoietic Cell Transplant

Yenny Alejandra Moreno Vanegas, Urshila Durani, Christine Goth, Nandita Khera, Zhuo Li, Hemant S. Murthy, Vivek Roy, James M. Foran, Ernesto Ayala, Mohamed A. Kharfan-Dabaja, Jasmine Zain, Madiha Iqbal
Journal: Blood
Blood (2024) 144 (Supplement 1): 507.
https://doi.org/10.1182/blood-2024-206020
Published: 2024
Journal Articles

Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas

Clinical Trials & Observations
Udit Yadav, Shaji K. Kumar, Linda B. Baughn, Angela Dispenzieri, Patricia Greipp, Rhett Ketterling, Dragan Jevremovic, Francis K. Buadi, David Dingli, Martha Q. Lacy, Rafael Fonseca, P. Leif Bergsagel, Sikander Ailawadhi, Vivek Roy, Ricardo Parrondo, Taimur Sher, Suzanne R. Hayman, Prashant Kapoor, Nelson Leung, Joselle Cook, Moritz Binder, Eli Muchtar, Rahma Warsame, Taxiarchis V. Kourelis, Ronald S. Go, Yi Lin, Abhishek Seth, Scott C. Lester, William G. Breen, Robert A. Kyle, Morie A. Gertz, S. Vincent Rajkumar, Wilson I. Gonsalves
Journal: Blood
Blood (2023) 142 (22): 1871–1878.
https://doi.org/10.1182/blood.2023021187
Published: 2023
Includes: Supplemental data
Journal Articles

Patient Awareness of CAR-T and Bispecific Antibody Treatments for Multiple Myeloma: Real-World Learnings and Disparities

Yaw Adu, Saurav Das, Dhaani Ailawadhi, Andre Fernandez, Ricardo Parrondo, Vivek Roy, Taimur Sher, Sean O'Connell, Ahsan Rasheed, Asher A Chanan- Khan, Sikander Ailawadhi
Journal: Blood
Blood (2023) 142 (Supplement 1): 2418.
https://doi.org/10.1182/blood-2023-189642
Published: 2023
Journal Articles

Trial in Progress: A Phase 1 Study of KTX-1001, an Oral, First-in-Class, Selective MMSET Inhibitor in Patients with Relapsed and Refractory Multiple Myeloma

Jesus G. Berdeja, David Dingli, Sagar Lonial, Andrew J. Yee, Alfred Chung, Cristina Gasparetto, P. Leif Bergsagel, Vivek Roy, Al-Ola Abdallah, Sharmilan Thanendrarajan, Aimaz Afrough, Laura Rosiñol, Suzanne Trudel, Paula Rodriguez Otero, Cyrille Touzeau, Pierre Bories, Soo Bang, Terry Connolly, Michelle Kim, Chad A. Lewis, Bao-Van Tran Linberg, M. Travis Quigley, Ola Landgren, Saad Z Usmani, Maria-Victoria Mateos, David S. Siegel
Journal: Blood
Blood (2023) 142 (Supplement 1): 3391.
https://doi.org/10.1182/blood-2023-174550
Published: 2023
Journal Articles

Detectable Somatic Variants Using Next Generation Sequencing (NGS) Post Allogeneic Hematopoietic Cell Transplant (Allo-HCT) Predict for High Relapse Risk in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Himil Mahadevia, Liuyan Jiang, Zhuo Li, Hemant S. Murthy, James M. Foran, Vivek Roy, Ernesto Ayala, Mohamed A. Kharfan-Dabaja, Madiha Iqbal
Journal: Blood
Blood (2023) 142 (Supplement 1): 4983.
https://doi.org/10.1182/blood-2023-190202
Published: 2023
Journal Articles

Understanding Patient Perspective, Challenges, Behavioral Patterns, and Preferences Towards Participation in Multiple Myeloma Clinical Trials: A Prospective Study

Sikander Ailawadhi, Jay R. Hydren, Leyla Bojanini, Nathan W. Sweeney, Felicia Seng, Mizba Baksh, Ahsan Rasheed, Mays Abdulazeez, Meghna Ailawadhi, Keren George, Ricardo D Parrondo, Vivek Roy, Victoria R. Alegria, Pooja Advani, Rami Manochakian, Jason S. Starr, Taimur Sher, Jennifer M. Ahlstrom, Asher Chanan-Khan
Journal: Blood
Blood (2022) 140 (Supplement 1): 7941–7942.
https://doi.org/10.1182/blood-2022-167005
Published: 2022
Journal Articles

Patients with Monoclonal Gammopathy Have a High Rate of Second Symptomatic COVID-19 Infection Even after a Prior COVID-19 Infection and Vaccination

Saurabh Zanwar, Matthew Ho, Francis K. Buadi, Sikander Ailawadhi, Jeremy T. Larsen, P. Leif Bergsagel, Moritz Binder, Asher Chanan-Khan, David Dingli, Angela Dispenzieri, Rafael Fonseca, Morie A. Gertz, Wilson I. Gonsalves, Ronald Go, Suzanne R. Hayman, Prashant Kapoor, Taxiarchis Kourelis, Martha Q. Lacy, Nelson Leung, Yi Lin, Eli Muchtar, Vivek Roy, Taimur Sher, Rahma M Warsame, Amie Fonder, Miriam A. Hobbs, Yi L. Hwa, Robert A. Kyle, S. Vincent Rajkumar, Shaji K Kumar
Journal: Blood
Blood (2022) 140 (Supplement 1): 10017–10019.
https://doi.org/10.1182/blood-2022-167181
Published: 2022
Journal Articles

Peri-Transplant and Maintenance Daratumumab for Minimal Residual Disease (MRD) Eradication in Transplant-Eligible Multiple Myeloma (MM) Patients

Sikander Ailawadhi, Ricardo D Parrondo, Gabriela Perez, Mohamed A. Kharfan-Dabaja, Hemant S. Murthy, Ernesto Ayala, Patrick J O'Brien, Vivek Roy, Victoria R. Alegria, Ashley Zimmerman, Dustin Chapin, Stephanie Lanier, Carly Kasik, Schannon Bradley, Taimur Sher, Aneel Paulus, Asher Chanan-Khan
Journal: Blood
Blood (2022) 140 (Supplement 1): 10165–10166.
https://doi.org/10.1182/blood-2022-165209
Published: 2022
Journal Articles

Therapeutic Outcomes of Relapsed-Refractory Multiple Myeloma Patients with 1q21+Treated with Daratumumab-Based Regimens: A Retrospective Analysis

Ricardo D Parrondo, Lindsay Brooke Gardner, Mohamad Alhaj Moustafa, Vivek Roy, Taimur Sher, Ahsan Rasheed, Rahma M Warsame, Jeremy T. Larsen, Wilson I. Gonsalves, Taxiarchis Kourelis, Prashant Kapoor, Rafael Fonseca, Asher Chanan-Khan, Sikander Ailawadhi
Journal: Blood
Blood (2022) 140 (Supplement 1): 7237–7238.
https://doi.org/10.1182/blood-2022-169533
Published: 2022
Journal Articles

Phase II Trial of Elotuzumab with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) in the Post-Daratumumab Progression Setting

Sikander Ailawadhi, Ricardo D Parrondo, Betsy Laplant, Victoria R. Alegria, Jamie B Elliott, Taimur Sher, Aneel Paulus, Dustin Chapin, Keisha Heslop, Asher Chanan-Khan, Vivek Roy
Journal: Blood
Blood (2022) 140 (Supplement 1): 4450–4451.
https://doi.org/10.1182/blood-2022-164656
Published: 2022
Journal Articles

Time-Limited Maintenance with Ibrutinib after First-Line Therapy and the Incremental Impact on Minimal Residual Disease (MRD) for Patients with Chronic Lymphocytic Leukemia (CLL)

Sikander Ailawadhi, Ricardo D Parrondo, Aneel Paulus, Betsy Laplant, Victoria R. Alegria, Ashley Zimmerman, Dustin Chapin, Taimur Sher, Vivek Roy, Asher Chanan-Khan
Journal: Blood
Blood (2022) 140 (Supplement 1): 9904–9905.
https://doi.org/10.1182/blood-2022-164667
Published: 2022
Journal Articles

Phase II Study of Ibrutinib in Combination with Ixazomib in Patients with Waldenström Macroglobulinemia (WM)

Sikander Ailawadhi, Ricardo D Parrondo, Betsy Laplant, Victoria R. Alegria, Jamie B Elliott, Ashley Zimmerman, Keisha Heslop, Dustin Chapin, Taimur Sher, Vivek Roy, Ahsan Rasheed, Aneel Paulus, Asher Chanan-Khan
Journal: Blood
Blood (2022) 140 (Supplement 1): 9331–9332.
https://doi.org/10.1182/blood-2022-165377
Published: 2022
Journal Articles

Risk factors for severe infection and mortality in COVID-19 and monoclonal gammopathy of undetermined significance

Matthew Ho, Saurabh Zanwar, Francis K. Buadi, Sikander Ailawadhi, Jeremy Larsen, Leif Bergsagel, Moritz Binder, Asher Chanan-Khan, David Dingli, Angela Dispenzieri, Rafael Fonseca, Morie A. Gertz, Wilson Gonsalves, Ronald S. Go, Suzanne Hayman, Prashant Kapoor, Taxiarchis Kourelis, Martha Q. Lacy, Nelson Leung, Yi Lin, Eli Muchtar, Vivek Roy, Taimur Sher, Rahma Warsame, Amie Fonder, Miriam Hobbs, Yi L. Hwa, Robert A. Kyle, S. Vincent Rajkumar, Shaji Kumar
Journal: Blood
Blood (2022) 140 (18): 1997–2000.
https://doi.org/10.1182/blood.2022017616
Published: 2022
Includes: Supplemental data
Journal Articles

A Calcineurin Inhibitor Free Graft Versus Host Disease (GVHD) Prophylaxis for Patients Undergoing Matched Related (MRD) and Matched Unrelated Donor (MUD) Allogeneic Hematopoietic Cell Transplant (Allo-HCT)

Madiha Iqbal, Felipe Andres Mendieta Nieto, Kaitlyn M Brannick, Zhuo Li, Hemant S. Murthy, James M. Foran, Vivek Roy, Mohamed A. Kharfan-Dabaja, Ernesto Ayala
Journal: Blood
Blood (2021) 138 (Supplement 1): 3893.
https://doi.org/10.1182/blood-2021-151845
Published: 2021
Journal Articles

Phase 1b/2 Study of the First-in-Class SUMO-Activating Enzyme Inhibitor TAK-981 in Combination with Monoclonal Antibodies in Patients with Triple-Class Refractory Multiple Myeloma

Sagar Lonial, Stefano R. Tarantolo, Ralph V. Boccia, Habte Yimer, Moshe Y. Levy, Rafat Abonour, Meera Mohan, Vivek Roy, Jeremy T. Larsen, Saulius K. Girnius, Cara A. Rosenbaum, Omar Nadeem, Deborah Berg, Bo Chao, Allison J Berger, Akito Nakamura, Yuhong Zhang, Keli Song, Christine K. Ward, Igor Proscurshim, Shaji Kumar
Journal: Blood
Blood (2021) 138 (Supplement 1): 2742.
https://doi.org/10.1182/blood-2021-148385
Published: 2021